retatrutide vs cagrilintide
updated
retatrutide (tier S) vs cagrilintide (tier B): what each is, why each got its grade, half-life and source counts side by side.
retatrutide · tier S
the most potent weight loss drug ever tested. 24.2% in phase 2, then 28.3% in TRIUMPH-1 phase 3, 30.3% at two years. not approved yet.
tier rationale
now that the pivotal phase 3 obesity trial has read out (TRIUMPH-1: 28.3% weight loss at 12mg over 80 weeks, 30.3% at two years), reta has the strongest published obesity-drug efficacy in the catalog. Bariatric-surgery territory from a weekly shot. triple receptor mechanism adds glucagon agonism on top of tirz's dual mechanism, which pushes lipolysis and energy expenditure. S-tier based on phase 3 efficacy, but with meaningful open questions on safety and no announced approval date.
cagrilintide · tier B
novo's long-acting amylin analog. 11.8% standalone weight loss in the phase-3 REDEFINE-1 trial (10.8% earlier in phase 2). the filed product is the cagrisema combo, not the monotherapy.
tier rationale
B-tier because the standalone is investigational and its strongest published number (11.8% in the phase-3 REDEFINE-1 trial) trails the FDA-grade obesity drugs. the mechanism is real and the data is real, including a within-trial win over liraglutide in phase 2. but the program that reached an FDA filing is the cagrisema combination, not the monotherapy, and the dedicated RENEW monotherapy phase-3 is still running. S is reserved for approved or dominant-evidence compounds; A is reserved for compounds in wide clinical use. cagrilintide alone is neither yet.
at a glance
| retatrutide | cagrilintide | |
|---|---|---|
| tier | S | B |
| category | weight loss | weight loss |
| sources | 27 | 4 |
| claims evaluated | 8 | 6 |
| half-life | ~6 days | ~7 days |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.